Dillman R O
Hoag Cancer Center, Newport Beach, California 92658-6100, USA. www.hoag.org
Cancer Biother Radiopharm. 1999 Dec;14(6):423-34. doi: 10.1089/cbr.1999.14.423.
It has been 15 years since the first positive clinical reports of Interleukin-2 (IL-2) appeared in the medical literature, ten years since moderate dose continuous infusion IL-2 was approved in Europe, and five years since high-dose bolus IL-2 was approved for general use in the United States. IL-2 is accepted as a standard treatment used alone, or in combination with chemotherapy or biotherapy in the management of metastatic melanoma and metastatic renal cell carcinoma. Various physicians utilize high-dose bolus IL-2, moderate-dose continuous infusion IL-2, and low-dose outpatient intravenous or subcutaneous IL-2. There is still no consensus regarding the best way to deliver IL-2 alone in terms of dose and schedule of administration from a risk-to-benefit standpoint. Despite yielding higher tumor response rates, regimens that combine IL-2 with chemotherapy and/or interferon have not produced better long-term survival.
自白细胞介素-2（IL-2）的首批阳性临床报告出现在医学文献中已有15年，自中等剂量持续输注IL-2在欧洲获批已有10年，自高剂量推注IL-2在美国获批普遍使用已有5年。IL-2被公认为是单独使用，或与化疗或生物疗法联合用于治疗转移性黑色素瘤和转移性肾细胞癌的标准疗法。不同的医生使用高剂量推注IL-2、中等剂量持续输注IL-2以及低剂量门诊静脉或皮下注射IL-2。从风险效益的角度来看，就单独给予IL-2的最佳剂量和给药方案而言，目前仍未达成共识。尽管联合使用IL-2与化疗和/或干扰素的方案产生了更高的肿瘤缓解率，但并未带来更好的长期生存率。
